Fundraising Fox

Cyclacel Pharmaceuticals

Berkeley Heights, US · Delaware corporation · 1 known investors

Biotech

Founders & leadership

SR
Spiro RombotisExecutive
PM
Paul McBarronExecutive
MH
Mark H. KirschbaumExecutive
GT
Gregory T. HradskyNamed on SEC filing
RJ
Robert J. SpeigelNamed on SEC filing
LS
Lloyd SemsNamed on SEC filing

Board

RS
Robert SpiegelBoard director
KW
Karin WalkerBoard director
CH
Christopher HenneyBoard director
SB
Samuel BarkerBoard director
BS
Brian SchwartzBoard director
KF
Kenneth FergusonBoard director

Investors · 1

Also in the syndicate · 1

H.C. Wainwright & Co.

Reported raises · per SEC filings

Form D private placements

$18.1M disclosed across 4 of 6 rounds · 2020–2025

▶$1MraisedMar 2025 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Avraham Ben-TzviDirector
  • Kiu Cu SengExecutive Officer
  • David NatanDirector
  • Kwang Fock ChongDirector
  • Datuk Dr. Doris Wong Sing EeExecutive Officer
Offering amount
$1M
Amount sold
$1M
First sale
Mar 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedFeb 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NatanDirector
  • David LazarExecutive Officer
  • Avraham Ben-TzviDirector
  • Paul McBarronDirector
  • Samuel BarkerDirector
  • Spiro RombotisDirector
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MofferedFeb 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul McBarronDirector
  • Avraham Ben-TzviDirector
  • David NatanDirector
  • Spiro RombotisDirector
  • David LazarExecutive Officer
  • Samuel BarkerDirector
Offering amount
$25M
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.1MraisedNov 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Spiro RombotisExecutive Officer, Director
  • Robert SpiegelDirector
  • Karin WalkerDirector
  • Christopher HenneyDirector
  • Samuel BarkerDirector
  • Brian SchwartzDirector
  • Paul McBarronExecutive Officer, Director
  • Kenneth FergusonDirector
Offering amount
$2.1M
Amount sold
$2.1M
Sales commissions
$190K
Placement agents
H.C. Wainwright & Co.
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedMay 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher HenneyDirector
  • Karin WalkerDirector
  • Spiro RombotisExecutive Officer, Director
  • Robert SpiegelDirector
  • Kenneth FergusonDirector
  • Brian SchwartzDirector
  • Paul McBarronExecutive Officer, Director
  • Samuel BarkerDirector
Offering amount
$8M
Amount sold
$8M
Sales commissions
$640K
Placement agents
H.C. Wainwright & Co.
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Karin WalkerDirector
  • Brian SchwartzDirector
  • Christopher S. HenneyDirector
  • Gregory T. HradskyDirector
  • Spiro RombotisExecutive Officer, Director
  • Robert J. SpeigelDirector
  • Samuel L. BarkerDirector
  • Paul McBarronExecutive Officer, Director
  • Mark H. KirschbaumExecutive Officer
  • Lloyd SemsDirector
Offering amount
$7M
Amount sold
$7M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Cyclacel Pharmaceuticals Reports Q1 2025 Financial Results and Strategic Focus Shifts to Plogosertib Development | Nasdaqnasdaq.com · May 2025Cyclacel Pharmaceuticals, Inc. SEC 10-K Report — TradingView Newstradingview.com · Apr 2025Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8 million in funding | MarketScreenermarketscreener.com · Feb 2025Cyclacel Pharmaceuticals Secures $3.1M Investment, Names David Lazar as Interim CEO Amid Restructuring | CYCC Stock Newsstocktitan.net · Jan 2025Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share | CYCC Stock Newsstocktitan.net · Nov 2024

Frequently asked questions

How much funding has Cyclacel Pharmaceuticals raised?
Cyclacel Pharmaceuticals has disclosed $18.1M raised across 4 of its 6 known rounds.
Where is Cyclacel Pharmaceuticals headquartered?
Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, US.